Related references
Note: Only part of the references are listed.Antisense oligonucleotides as a potential treatment for brain deficits observed in myotonic dystrophy type 1
Siham Ait Benichou et al.
GENE THERAPY (2022)
The sustained expression of Cas9 targeting toxic RNAs reverses disease phenotypes in mouse models of myotonic dystrophy type 1
Ranjan Batra et al.
NATURE BIOMEDICAL ENGINEERING (2021)
Modeling muscle regeneration in RNA toxicity mice
Ramesh S. Yadava et al.
HUMAN MOLECULAR GENETICS (2021)
Systemic therapy in an RNA toxicity mouse model with an antisense oligonucleotide therapy targeting a non-CUG sequence within the DMPK 3′UTR RNA
Ramesh S. Yadava et al.
HUMAN MOLECULAR GENETICS (2020)
Mechanisms of palmitic acid-conjugated antisense oligonucleotide distribution in mice
Alfred E. Chappell et al.
NUCLEIC ACIDS RESEARCH (2020)
Therapeutic Potential of AntagomiR-23b for Treating Myotonic Dystrophy
Estefania Cerro-Herreros et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2020)
Differential uptake, kinetics and mechanisms of intracellular trafficking of next-generation antisense oligonucleotides across human cancer cell lines
Emily Linnane et al.
NUCLEIC ACIDS RESEARCH (2019)
Conjugation of hydrophobic moieties enhances potency of antisense oligonucleotides in the muscle of rodents and non-human primates
Michael E. Ostergaard et al.
NUCLEIC ACIDS RESEARCH (2019)
Fatty acid conjugation enhances potency of antisense oligonucleotides in muscle
Thazha P. Prakash et al.
NUCLEIC ACIDS RESEARCH (2019)
Peptide-conjugated oligonucleotides evoke long-lasting myotonic dystrophy correction in patient- derived cells and mice
Arnaud F. Klein et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Improved mobility with metformin in patients with myotonic dystrophy type 1: a randomized controlled trial
Guillaume Bassez et al.
BRAIN (2018)
Non-invasive monitoring of alternative splicing outcomes to identify candidate therapies for myotonic dystrophy type 1
Ningyan Hu et al.
NATURE COMMUNICATIONS (2018)
Targeting deregulated AMPK/mTORC1 pathways improves muscle function in myotonic dystrophy type I
Marielle Brockhoff et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Cellular uptake and trafficking of antisense oligonucleotides
Stanley T. Crooke et al.
NATURE BIOTECHNOLOGY (2017)
Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides
Mark J. Graham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Targeting DMPK with Antisense Oligonucleotide Improves Muscle Strength in Myotonic Dystrophy Type 1 Mice
Dominic Jauvin et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2017)
Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials
Nicholas J. Viney et al.
LANCET (2016)
Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides
Richard S. Geary et al.
ADVANCED DRUG DELIVERY REVIEWS (2015)
Efficient Synthesis and Biological Evaluation of 5′-GalNAc Conjugated Antisense Oligonucleotides
Michael E. Ostergaard et al.
BIOCONJUGATE CHEMISTRY (2015)
Therapeutic Approaches for Dominant Muscle Diseases: Highlight on Myotonic Dystrophy
A. F. Klein et al.
CURRENT GENE THERAPY (2015)
MBNL Sequestration by Toxic RNAs and RNA Misprocessing in the Myotonic Dystrophy Brain
Marianne Goodwin et al.
CELL REPORTS (2015)
Antisense Oligonucleotide Therapies: The Promise and the Challenges from a Toxicologic Pathologist's Perspective
Kendall S. Frazier
TOXICOLOGIC PATHOLOGY (2015)
Identification and Characterization of Modified Antisense Oligonucleotides Targeting DMPK in Mice and Nonhuman Primates for the Treatment of Myotonic Dystrophy Type 1
Sanjay K. Pandey et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2015)
Loss of MBNL Leads to Disruption of Developmentally Regulated Alternative Polyadenylation in RNA-Mediated Disease
Ranjan Batra et al.
MOLECULAR CELL (2014)
Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice
Thazha P. Prakash et al.
NUCLEIC ACIDS RESEARCH (2014)
Clinical pharmacokinetics of second generation antisense oligonucleotides
Rosie Z. Yu et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2013)
Preclinical Evaluation of the Toxicological Effects of a Novel Constrained Ethyl Modified Antisense Compound Targeting Signal Transducer and Activator of Transcription 3 in Mice and Cynomolgus Monkeys
Sebastien A. Burel et al.
NUCLEIC ACID THERAPEUTICS (2013)
Transcriptome-wide Regulation of Pre-mRNA Splicing and mRNA Localization by Muscleblind Proteins
Eric T. Wang et al.
CELL (2012)
GSK3β mediates muscle pathology in myotonic dystrophy
Karlie Jones et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
Targeting nuclear RNA for in vivo correction of myotonic dystrophy
Thurman M. Wheeler et al.
NATURE (2012)
RNase H-mediated degradation of toxic RNA in myotonic dystrophy type 1
Johanna E. Lee et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Molecular, Physiological, and Motor Performance Defects in DMSXL Mice Carrying >1,000 CTG Repeats from the Human DM1 Locus
Aline Huguet et al.
PLOS GENETICS (2012)
Myotonic dystrophy, when simple repeats reveal complex pathogenic entities: new findings and future challenges
Geraldine Sicot et al.
HUMAN MOLECULAR GENETICS (2011)
Overcoming biological barriers to in vivo efficacy of antisense oligonucleotides
Paul J. White et al.
EXPERT REVIEWS IN MOLECULAR MEDICINE (2009)
Electrocardiographic abnormalities and sudden death in myotonic dystrophy type 1
William J. Groh et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
A postnatal switch of CELF and MBNL proteins reprograms alternative splicing in the developing heart
Auinash Kalsotra et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Controlled intracellular localization and enhanced antisense effect of oligonucleotides by chemical conjugation
T Kubo et al.
ORGANIC & BIOMOLECULAR CHEMISTRY (2005)
Controlled intracellular localization and enhanced antisense effect of oligonucleotides by chemical conjugation (vol 3, pg 3257, 2005)
T Kubo et al.
ORGANIC & BIOMOLECULAR CHEMISTRY (2005)
RNA CUG repeats sequester CUGBP1 and alter protein levels and activity of CUGBP1
NA Timchenko et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Recruitment of human muscleblind proteins to (CUG)(n) expansions associated with myotonic dystrophy
JW Miller et al.
EMBO JOURNAL (2000)
Share Paper
